Clinical Trial Search

Primary: Estimated Mean Change of the Montreal Cognitive Assessment (MoCA) — 3.356; -0.085 score on a scale

Primary: Functionality in Activities of Daily Living (Changes in Scores Approach) — 0.1; 0; -0.1; -0.2 units on a scale — p=.145

Primary: Change in Objective Cognitive Performance Composite z Score — .24; .14 Z score

Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Rey Auditory Verbal Learning Test (Total Delayed Recall) — 6.43; 7.83 score on a scale — p=0.11

Primary: Composite Cognitive Score — 45.5; 47.9 units on a scale

Primary: Double Blind (DB) Phase: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24 — -2.06; -2.64 score on a…

Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items

Primary: Change in Executive Function — 0.32; 0.36 z-score

Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants

Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio

Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2

Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants

Primary: Agreement Analysis (Agreement to Reference Standard) - Test Group — 76; 18; 2; 8 Participants

Primary: Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24 — -10.60; -4.49 points on a scale — p=< 0.0001

Primary: Change in Readiness to Engage in ACP (ACP Engagement Scale) — 1.92; 1.54; 2.77; 2.00 units on a scale

Primary: Rivermead Behavioral Memory Test — 11.08; 11.2; 12.31 units on a scale

Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008

Primary: Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI — 5.87; 8.14; 6.26; 7.08 percent change per participant year

Primary: Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent) — 32.4; 31.6 % 10 yr Risk

Primary: Nitric Oxide (NO)-Mediated Endothelium-dependent Dilation (EDD) — 70; 74 percentage — p=>0.05

Primary: Mean MoCA Score at Week 1 and the End of the 12-week Therapy — 19.42; 24 score on a scale — p=<0.00001

Primary: Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months — -3.83 standard uptake value ratio

Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight

Primary: Number of Participants With Poor Stroke Outcome at Hospital Discharge as Measured by the Modified Rankin Scale (mR 3-6) — 84; 99; 96; 87 Participants

Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409

Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005

Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation

Primary: New Occurrence in Dementia Care-A Composite Endpoint Including New Cognitive Diagnoses, Laboratory Investigations Related to Cognitive Impairment, New Dementia…